Chronic pains
22 October 2019

The $54 bln maker of Gaviscon antacid is still having trouble absorbing its 2017 purchase of baby food maker Mead Johnson, says outgoing CFO Adrian Hennah. The result is a second cut in the 2019 sales target. The recognition is welcome, but a full recovery may require more pain.